- Remove All
Your shopping cart is currently empty
Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer. PSCA Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with N-hFc tag. The predicted molecular weight is 34.5 kDa and the accession number is P57096.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 μg | $58 | 7-10 days | |
| 10 μg | $92 | 7-10 days | |
| 20 μg | $148 | 7-10 days | |
| 50 μg | $289 | 7-10 days | |
| 100 μg | $487 | 7-10 days | |
| 200 μg | $883 | 7-10 days | |
| 500 μg | $1,950 | 7-10 days |
| Biological Activity | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| Description | Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer. PSCA Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with N-hFc tag. The predicted molecular weight is 34.5 kDa and the accession number is P57096. |
| Species | Mouse |
| Expression System | HEK293 Cells |
| Tag | N-hFc |
| Accession Number | P57096 |
| Synonyms | UNQ206,PSCA,PRO232 |
| Construction | Leu21-Asn95 |
| Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Molecular Weight | 34.5 kDa (predicted). Due to glycosylation, the protein migrates to 40-60 kDa based on Tris-Bis PAGE result. |
| Endotoxin | < 1 EU/μg by the LAL method. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
| Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. |
| Research Background | Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.